Andrew Galler
speaker
96 appearances
1 recordings
1 series
first heard Feb 2026
last heard 3 Feb
Andrew Galler’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 1 in all, peaking in Feb 2026 with 1.
Appearances
Today's show is brought to you by Vanguard.
To all the financial advisors listening, let's talk bonds for a minute.
Capturing value and fixed income is not easy.
Bond markets are massive, murky, and let's be real, lots of firms throw a couple flashy funds your way and call it a day.
But not Vanguard.
At Vanguard, institutional quality isn't a tagline.
It's a commitment to your clients.
We're talking top-grade products across the board of over 80 bond funds.
actively managed by a 200-person global squad of sector specialists, analysts, and traders.
These folks live and breathe fixed income.
So if you're looking to give your clients consistent results year in and year out, go see the record for yourself at Vanguard.com slash audio.
That's Vanguard.com slash audio.
All investing is subject to risk.
Vanguard Marketing Corporation Distributor.
Welcome, everyone, to another episode of the Vanguards of Healthcare podcast.
I'm your host, Andrew Galler, one of the biopharmaceutical analysts in Bloomberg Intelligence.
Bloomberg Intelligence is Bloomberg's corporate research arm, encompassing over 500 analysts worldwide.
I'm pleased to be joined today by Robert Blum, President and CEO of Cytokinetics.
Robert, thanks for joining us today.
So maybe just to kick it off, do you want to give everyone a brief overview of cytokinetics as a company and maybe the 30-year journey you've had from founding to the recent approval of your first FDA-approved drug, mycorrhizal?
Showing 1–20 of 96 · page 1 of 5
Next →